Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spartan Bioscience and NorDiag sign new collaboration agreement
The goal of the partnership is to provide an end-to-end solution for DNA analysis that is truly fast, affordable and user friendly. The basis of the collaboration is
The goal of the partnership is to provide an end-to-end solution for DNA analysis that is truly fast, affordable and user friendly. The basis of the collaboration is
The company will initiate clinical trials in November 2008 to evaluate this drug, a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor, for the treatment of infections.
With the FDA investigational device exemption (IDE) approval in place, Dune is launching a nationwide US clinical trial of MarginProbe, which uses radio frequency spectroscopy to characterize breast
Data from two long-term, open-label extension studies has showed that Enbrel provided improvement in the signs and symptoms of rheumatoid arthritis (RA) that was maintained for up to
In its final guidance, the National Institute for Health and Clinical Excellence (NICE) has confirmed that spinal cord stimulation (SCS) is both safe and clinically effective in these
According to the company, the Curos Port Protector is designed to reduce patient exposure to the risks of hospital acquired bloodstream infections and help maintain hospital infection control
The patents for the company’s Skinfusion technology cover the intermediate formulation during manufacturing and the finished product for a transdermal patch containing estrogen and progestin used in contraception.
Bristol-Myers Squibb collaborates with ImClone on Erbitux in North America and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada. Erbitux is approved by
According to the company, Claro, the first hand-held device to use intense pulsed light for treatment of acne, will be available by prescription January 2009 from medical professionals,
The Phase I/IIa inter-patient dose escalation study will assess the safety and tolerability of repeated administration of Cytheris’s investigative immunotherapy, recombinant human Interleukin-7 (CYT107), as an add-on therapy